Kymera Therapeutics, Inc. KYMR
111.95
(3.86)
(3.33%)
as of 25 Sep
- Market cap
- $9.7B
- P/E
- 0.0×
Follow KYMR
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
112.98 | 167.66 | 157.81 | 107.22 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(182.26) | (98.49) | (91.44) | (208.23) | |
P/B ratio |
5.22 | 4.16 | 5.28 | 7.46 | |
Price to Tangible BV |
5.22 | 4.16 | 5.28 | 7.46 | |
EV/Sales |
101.46 | 146.07 | 145.19 | 100.65 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(19.47) | (24.59) | (30.81) | (44.63) | |
EV/FCF |
(19.28) | (24.44) | (30.63) | (44.41) | |
Quick Ratio |
7.07 | 10.19 | 10.39 | 9.97 | |
Current Ratio |
7.38 | 10.47 | 10.81 | 10.34 | |
Net Debt/EBITDA |
5.44 | 8.65 | 7.66 | 9.09 | |
Debt/Assets |
0.16% | 0.08% | 0.07% | 0.05% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.04 | 0.03 | 0.04 | 0.08 | |
Operating CF/Net income |
0.33 | 0.77 | 1.28 | 0.88 | |
Capex/Depreciation |
4.64 | 8.15 | 0.61 | 1.59 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,680.68% | 2,919.92% | 285.65% | 183.82% | |
Selling, General and Administrative Expense of Revenue |
627.21% | 589.86% | 59.24% | 32.50% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
571.71% | 503.41% | 46.58% | 29.14% | |
Graham Net Nets |
0.08 | 0.11 | 0.07 | 0.05 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.34%) | (4.73%) | (4.29%) | (2.83%) | |
Free Cash Flow Yield |
(4.66%) | (3.56%) | (3.00%) | (2.11%) | |
Revenue per Share |
0.03 | 0.03 | 0.35 | 0.66 | |
Operating CF per Share |
(0.31) | (0.79) | (0.91) | (0.55) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.31) | (0.79) | (0.92) | (0.56) | |
Cash per Share |
5.79 | 10.04 | 6.67 | 7.04 | |
Shareholders Equity per Share |
10.84 | 18.70 | 15.79 | 15.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.84 | 18.70 | 15.79 | 15.37 | |
Free Cash Flow |
(27.29) | (66.85) | (89.27) | (54.54) | |
Working Capital |
456.72 | 788.00 | 614.79 | 665.94 | |
Capital Expenditures |
(0.18) | (0.11) | (0.43) | (0.47) | |
Net Current Asset Value |
372.51 | 708.07 | 548.05 | 601.08 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.07 | 0.04 | 0.01 | 0.01 | |
Net Profit Margin |
(2,973.05%) | (3,029.64%) | (201.47%) | (94.17%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | — | 12.06 | |
Average Payables |
6.00 | 5.00 | 11.55 | 7.35 | |
Average Assets |
1,068.44 | 1,360.42 | 1,293.66 | 1,388.26 | |
Average Common Equity |
919.59 | 1,207.64 | 1,162.94 | 1,240.37 |
Columns are period end dates